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years (QALY), costs and the incremental cost-effectiveness and cost-utility ratio 
(ICER and ICUR) of PET-CT versus CT based radiotherapy planning. Model outcomes 
were obtained from averaging the outcome for 50 000 simulated patients. To present 
uncertainty, a probabilistic sensitivity analysis was done. In scenario analyses, we 
explored the effect of varying the input parameters for costs and QALYs and the 
effect of changing the assumptions regarding the multi-state model. Results: The 
incremental costs of PET-CT based planning were € 534 (95% CI: € -4670 – € 6080) for 
0,43 incremental LYs (95% CI: 0,31 – 0,52) and 0,33 QALYs gained (95% CI: 0,26 – 0,45). 
The base-case scenario resulted in an ICER of € 1242 per LY gained and an ICUR 
of € 1618 per QALY gained. The probabilistic sensitivity analysis gave a 41% prob-
ability that PET-CT based planning improves health outcomes at reduced costs and 
a 59% probability that PET-CT based planning is more effective at slightly higher 
costs. ConClusions: PET-based radiotherapy planning for non-small cell lung 
cancer is highly cost-effective compared to CT-based planning.
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objeCtives: The cost-effectiveness of genetic testing for Lynch Syndrome for 
patients newly diagnosed with colorectal cancer in the UK has not previously been 
estimated. Therefore, the cost-effectiveness of nine testing strategies were simulta-
neously compared using a detailed and rigorous mathematical model. Methods: 
In the base case analysis, probands were tested only if aged 50 or below. Testing 
strategies included use of family history, tumour-based tests and genetic testing. 
The clinical pathways of thousands of individual patients diagnosed with colorectal 
cancer (CRC) and their relatives were simulated. For each person, the total costs 
and quality-adjusted life years (QALYs) were calculated using methodology recom-
mended by the National Institute of Health and Care Excellence (NICE). Simulated 
clinical events included incidence of CRC and endometrial cancer (EC); surgery for 
CRC and EC, colonoscopies (including bleeding and perforation), mortality from 
CRC, EC, colonoscopy and background causes. A proportion of people diagnosed 
with Lynch Syndrome were assumed to receive prophylactic hysterectomy and 
to undergo biennial colonoscopies (assumed to reduce the incidence and stage 
of colorectal cancer). The costs of treating patients with CRC with surgery, chem-
otherapy, radiotherapy, stoma care and palliative care were captured. Similarly, 
the costs of treating patients with EC with chemotherapy and radiotherapy were 
included. Results: The life expectancies of probands and relatives with Lynch 
Syndrome are estimated to increase by up to 1.6 years, depending on the strategy 
for genetic testing. All testing strategies are predicted to offer good value for money 
versus no testing, with all incremental cost-effectiveness ratios below the UK basic 
cost-effectiveness threshold of £20,000 per QALY. Universal genetic testing is pre-
dicted to offer poor value for money versus targeted genetic testing. ConClusions: 
Results suggest that targeted genetic testing for Lynch Syndrome for patients with 
newly diagnosed CRC in the UK is a good use of limited financial resources.
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objeCtives: The PillCam COLON2 is a colon capsule endoscopy (CCE) that 
makes a minimally-invasive colonoscopy possible and is expected to improve 
detailed examination rate which have been identified as a problem concerning a 
population-based colorectal cancer (CRC) screening system in Japan. The objective 
of this analysis was to evaluate the cost-effectiveness of CCE if newly introduced 
into the current population-based CRC screening system in Japan. Methods: The 
subject of this analysis was a sequential screening system for which CCE has been 
incorporated (immunochemical fecal occult blood test (IFOBT) → detailed exami-
nation by CCE → detailed examination by colonoscopy) and the comparator was 
the conventional sequential screening system (IFOBT → detailed examination by 
colonoscopy). The target population includes asymptomatic adults aged 40 years 
old and a lifelong simulation was conducted using a Markov model which consists 
of 8 states, no polyp, adenomatous polyp (≤ 5mm, 6-9mm and ≥ 10mm), local-
ized CRC, regional CRC, distant CRC and death. The efficacy measures were life 
year and quality-adjusted life year (QALY). The analysis was conducted from the 
perspective of the payer and only direct medical costs were considered. Results: 
The incremental cost effectiveness ratio (ICER) observed when incorporating CCE 
into the conventional screening system was € 59,911 per QALY, € 25,060 per QALY 
and € 14,905 per QALY when assuming a 10%, a 20% and a 30% improvements in 
detailed examination rates (1 Euro= 128 JPY). Therefore, the introduction of CCE 
was determined to be cost-effective if the detailed examination rate increased by 
20% or more relative to current rate with CCE introduction. ConClusions: Based 
on this analysis, the introduction of CCE into the conventional population-based 
screening system in Japan is shown to be cost-effective. The cost-effectiveness of 
CCE is primarily dependent on the degree of improvement in the current detailed 
examination rate.
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aprepitant price. ConClusions: The using aprepitant plus standard antiemetic 
therapy was more effective and economically justified treatment option for preven-
tion of nausea and vomiting associated with highly and moderately emetogenic 
cancer chemotherapy.
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objeCtives: In Norway, breast cancer represented 23% of all new cancer cases 
between 2004 and 2008, and was a leading cause of mortality representing 13% of all 
cancer deaths. The objective of this study was to perform an economic evaluation 
of fulvestrant 500 mg compared with anastrozole and letrozole used as second line 
endocrine therapies in the treatment of advanced breast cancer in post-menopausal 
women in Norway. Methods: The economic analysis was conducted by using a 
simulation model estimating progression-free survival, overall survival and associ-
ated costs and utility gains over the expected lifetime of the patients. As there are 
no head-to-head trials comparing fulvestrant 500 mg with aromatase inhibitors, 
the clinical evidence for the comparative effectiveness was obtained from a net-
work meta-analysis. The economic evaluation was conducted from a health care 
perspective, with costs and resource use based on published sources and expert 
assessment. Results: The cost-effectiveness ratio of fulvestrant 500 mg versus 
anastrozole 1 mg was 36,000 EUR per quality-adjusted life year (QALY), with incre-
mental costs of 9,600 EUR and incremental QALYs of 0.27. The cost-effectiveness 
ratio of fulvestrant 500 mg versus letrozole 2.5 mg was 62,000 EUR per QALY, with 
incremental costs of 21,000 EUR and incremental QALYs of 0.34. In the sensitivity 
analysis the results were stable for variations of key parameters, such as the time 
horizon, the hazard ratios for overall survival, the choice of parametric distribution 
for progression-free survival and the discount rate. ConClusions: Given an infor-
mal cost-effectiveness threshold of around 70,000 EUR/QALY in Norway, the results 
of the economic evaluations suggest that fulvestrant 500 mg is a cost-effective 
treatment compared with alternative treatments such as anastrozole and letrozole. 
These findings indicate that fulvestrant 500 mg is a valuable treatment option for 
patients with advanced breast cancer in Norway.
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objeCtives: Comorbid major depression occurs in approximately ten percent of peo-
ple suffering from a chronic medical condition such as cancer. A ‘collaborative care’ 
approach can be used to systematically identify and treat comorbid major depression. 
However, we lack information on cost-effectiveness of overall approach as economic 
evaluations published to date have focused solely on the treatment stage. We there-
fore aimed to use the best available evidence to estimate the cost-effectiveness of the 
whole approach (both systematic identification and systematic treatment) compared 
with usual practice, for patients attending specialist cancer clinics. Methods: A 
cost-effectiveness analysis using a decision analytic model structured to reflect both 
the identification and treatment processes. Evidence was taken from reviews of rel-
evant clinical trials and from observational studies, together with data from a large 
depression screening service. Sensitivity and scenario analyses were undertaken 
to determine the effects of variations in depression incidence rates, time horizons, 
patient characteristics and alternative estimates of treatment effect. Probabilistic 
sensitivity analysis was also undertaken. Results: Systematic depression manage-
ment generated more costs than usual practice, but also more quality adjusted life 
years (QALYs). The incremental cost-effectiveness ratio was £11,765 per QALY and the 
probabilities of systematic depression management being cost-effective at thresholds 
of £20,000 and £30,000 per QALY were 0.998 and 1 respectively. Findings were robust to 
tests of variation in key model parameters. ConClusions: A combined approach to 
the systematic identification and treatment of comorbid major depression in cancer 
patients is likely to be cost-effective at widely accepted threshold values. Systematic 
depression management may be a better way of generating QALYs for cancer patients 
than some existing medical and surgical treatments. It could potentially be applied 
to other chronic medical conditions.
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objeCtives: PET-based radiotherapy planning for selective lymph node irradiation 
is an example of the current tendency to individualize treatment in cancer. We 
evaluated the cost-effectiveness of individualized radiotherapy planning, compar-
ing PET-CT-based to CT-based radiotherapy treatment planning in non-small cell 
lung cancer. Methods: Our analysis uses a previously developed decision model. 
The model was based on data for 200 NSCLC patients with inoperable stage I-IIIB, 
provided by the Maastro Clinic. Transition rates in the model were estimated by 
multi-state statistical modelling and include the impact of patient and tumour 
features on disease progression. Resource use estimates, costs and utilities were 
obtained from the database of the Maastro Clinic, the literature and Dutch guide-
lines. Primary outcomes were the difference in life years (LY), quality adjusted life 
